Vimarsana
Biggest News Aggregation in the World

Page 11 - Eu Press News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eu Press. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eu Press Today - Breaking & Trending Today

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) - Vimarsana News

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-in-class medicine to treat an ultrarare, inherited form of high cholesterolNOVATO, Calif., Dec. 18,...

Vertex Achieves Certified Integration with the Mirakl Marketplace Platform - Vimarsana News

Vertex Achieves Certified Integration with the Mirakl Marketplace Platform

Vertex integration enables enterprise-class global indirect tax automation for Mirakl customers operating online marketplaces.KING OF PRUSSIA, Pa., Dec. 18, 2023 -- Vertex, Inc. , a global...

Iveco Group earns a Gold Medal in the EcoVadis Sustainability Rating having ranked in the Top 5% - Vimarsana News

Iveco Group earns a Gold Medal in the EcoVadis Sustainability Rating having ranked in the Top 5%

Turin, 18th December 2023. Iveco Group announces an important achievement in its sustainability journey. In its first year of participation in the EcoVadis sustainability assessment, the Group...

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial -December 15, 2023 at 07:23 am EST - Vimarsana News

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial -December 15, 2023 at 07:23 am EST

AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study will evaluate the effect of ACI-35.030...

Form 8.3 - [Molten Ventures plc - 14 12 2023] - (CGAML) - Vimarsana News

Form 8.3 - [Molten Ventures plc - 14 12 2023] - (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code 1.        KEY...